Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
March 13, 2025 08:03 ET
|
Folia Health
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence...
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
March 12, 2025 03:00 ET
|
Purespring Therapeutics
Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company as it advances pioneering kidney disease...
Spherix Global Insights and the American Kidney Fund Announce Strategic Partnership and Inaugural Initiative to Elevate the Voice of Kidney Patients – Beginning with IgAN Patients
February 19, 2025 10:14 ET
|
Spherix Global Insights
EXTON, PA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights is proud to announce its partnership with the American Kidney Fund (AKF), marking a significant milestone in a collaboration...
NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
December 02, 2024 08:30 ET
|
NovelMed Therapeutics Inc
--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder Up to 50% of IgAN patients with persistent proteinuria...
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024 07:00 ET
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024 07:01 ET
|
Travere Therapeutics, Inc.
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024.
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024 07:01 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 07:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 02:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...